Jubilant Pharmova Q2 Results: Net profit falls as sterile injectables, radiopharma earnings decline

ملخص مفصل

Among its business segments, Radiopharma revenue rose to ₹1,009.3 crore from ₹897.1 crore, while Allergy Immunotherapy revenue increased to ₹229.5 crore from ₹194 crore. Contract Development and Manufacturing Organisation (CDMO) – Sterile Injectables revenue grew to ₹559.6 crore from ₹411.5 crore.

Jubilant Pharmova Ltd on Friday (November 13) reported a 74.1% year-on-year decline in consolidated net profit to ₹31.2 crore for the second quarter of FY27, compared with ₹120.3 crore in the corresponding period last year.

Revenue from operations rose 20.5% to ₹2,370 crore from ₹1,966.4 crore a year earlier.

Earnings before interest, tax, depreciation and amortisation (EBITDA) declined 29.3% to ₹241 crore from ₹341 crore. The EBITDA margin contracted to 10.2% from 17.4% in the year-ago quarter.

ALSO READ | Jubilant Pharmova Q1 profit falls 45% as margins come under pressure

Among its business segments, Radiopharma revenue rose to ₹1,009.3 crore from ₹897.1 crore, while Allergy Immunotherapy revenue increased to ₹229.5 crore from ₹194 crore. Contract Development and Manufacturing Organisation (CDMO) – Sterile Injectables revenue grew to ₹559.6 crore from ₹411.5 crore.

Contract Research, Development and Manufacturing Organisation revenue stood at ₹344.8 crore, compared with ₹312.5 crore, while Generics revenue increased to ₹274.1 crore from ₹167 crore.

Segment results before tax, exceptional items and interest for Radiopharma declined to ₹69.8 crore from ₹95.5 crore. Allergy Immunotherapy segment results fell to ₹65.7 crore from ₹74.9 crore, while CDMO – Sterile Injectables reported a loss of ₹4.2 crore against a profit of ₹71 crore in the year-ago quarter.

ALSO READ | Jubilant Pharmova's US CMO facility gets 'Voluntary Action Indicated' classification

Contract Research, Development and Manufacturing Organisation segment results rose to ₹20 crore from ₹29 crore, while Generics reported a profit of ₹5.1 crore against a loss of ₹3.1 crore.

مطلع المقال، مقتطف من CNBC-TV18. لقراءة المقال كاملًا، افتحه على موقع الناشر.